vs
Insulet Corporation（PODD）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
Insulet Corporation的季度营收约是SCANSOURCE, INC.的1.0倍（$783.7M vs $766.5M），Insulet Corporation净利率更高（13.0% vs 2.2%，领先10.8%），Insulet Corporation同比增速更快（31.2% vs 2.5%），Insulet Corporation自由现金流更多（$48.2M vs $28.9M），过去两年Insulet Corporation的营收复合增速更高（33.2% vs 0.9%）
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
PODD vs SCSC — 直观对比
营收规模更大
PODD
是对方的1.0倍
$766.5M
营收增速更快
PODD
高出28.6%
2.5%
净利率更高
PODD
高出10.8%
2.2%
自由现金流更多
PODD
多$19.3M
$28.9M
两年增速更快
PODD
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $783.7M | $766.5M |
| 净利润 | $101.6M | $16.5M |
| 毛利率 | 72.6% | 13.4% |
| 营业利润率 | 18.7% | 2.3% |
| 净利率 | 13.0% | 2.2% |
| 营收同比 | 31.2% | 2.5% |
| 净利润同比 | 0.9% | -3.3% |
| 每股收益（稀释后） | $1.42 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PODDSCSC
| Q4 25 | $783.7M | $766.5M | ||
| Q3 25 | $706.3M | $739.6M | ||
| Q2 25 | $649.1M | $812.9M | ||
| Q1 25 | $569.0M | $704.8M | ||
| Q4 24 | $597.5M | $747.5M | ||
| Q3 24 | $543.9M | $775.6M | ||
| Q2 24 | $488.5M | $746.1M | ||
| Q1 24 | $441.7M | $752.6M |
净利润PODDSCSC
| Q4 25 | $101.6M | $16.5M | ||
| Q3 25 | $87.6M | $19.9M | ||
| Q2 25 | $22.5M | $20.1M | ||
| Q1 25 | $35.4M | $17.4M | ||
| Q4 24 | $100.7M | $17.1M | ||
| Q3 24 | $77.5M | $17.0M | ||
| Q2 24 | $188.6M | $16.1M | ||
| Q1 24 | $51.5M | $12.8M |
毛利率PODDSCSC
| Q4 25 | 72.6% | 13.4% | ||
| Q3 25 | 72.2% | 14.5% | ||
| Q2 25 | 69.7% | 12.9% | ||
| Q1 25 | 71.9% | 14.2% | ||
| Q4 24 | 72.1% | 13.6% | ||
| Q3 24 | 69.3% | 13.1% | ||
| Q2 24 | 67.7% | 13.0% | ||
| Q1 24 | 69.5% | 12.6% |
营业利润率PODDSCSC
| Q4 25 | 18.7% | 2.3% | ||
| Q3 25 | 16.7% | 3.5% | ||
| Q2 25 | 18.7% | 3.3% | ||
| Q1 25 | 15.6% | 3.2% | ||
| Q4 24 | 18.3% | 2.5% | ||
| Q3 24 | 16.2% | 2.3% | ||
| Q2 24 | 11.2% | 2.9% | ||
| Q1 24 | 12.9% | 2.3% |
净利率PODDSCSC
| Q4 25 | 13.0% | 2.2% | ||
| Q3 25 | 12.4% | 2.7% | ||
| Q2 25 | 3.5% | 2.5% | ||
| Q1 25 | 6.2% | 2.5% | ||
| Q4 24 | 16.9% | 2.3% | ||
| Q3 24 | 14.2% | 2.2% | ||
| Q2 24 | 38.6% | 2.2% | ||
| Q1 24 | 11.7% | 1.7% |
每股收益（稀释后）PODDSCSC
| Q4 25 | $1.42 | $0.75 | ||
| Q3 25 | $1.24 | $0.89 | ||
| Q2 25 | $0.32 | $0.87 | ||
| Q1 25 | $0.50 | $0.74 | ||
| Q4 24 | $1.38 | $0.70 | ||
| Q3 24 | $1.08 | $0.69 | ||
| Q2 24 | $2.59 | $0.66 | ||
| Q1 24 | $0.73 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $83.5M |
| 总债务越低越好 | $930.8M | — |
| 股东权益账面价值 | $1.5B | $910.9M |
| 总资产 | $3.2B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资PODDSCSC
| Q4 25 | — | $83.5M | ||
| Q3 25 | — | $124.9M | ||
| Q2 25 | — | $126.2M | ||
| Q1 25 | — | $146.3M | ||
| Q4 24 | — | $110.5M | ||
| Q3 24 | — | $145.0M | ||
| Q2 24 | — | $185.5M | ||
| Q1 24 | — | $159.1M |
总债务PODDSCSC
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | — | ||
| Q2 25 | $939.0M | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益PODDSCSC
| Q4 25 | $1.5B | $910.9M | ||
| Q3 25 | $1.4B | $914.0M | ||
| Q2 25 | $1.5B | $906.4M | ||
| Q1 25 | $1.3B | $901.7M | ||
| Q4 24 | $1.2B | $900.7M | ||
| Q3 24 | $1.1B | $920.9M | ||
| Q2 24 | $998.4M | $924.3M | ||
| Q1 24 | $790.7M | $944.1M |
总资产PODDSCSC
| Q4 25 | $3.2B | $1.7B | ||
| Q3 25 | $3.0B | $1.7B | ||
| Q2 25 | $3.5B | $1.8B | ||
| Q1 25 | $3.5B | $1.7B | ||
| Q4 24 | $3.1B | $1.7B | ||
| Q3 24 | $3.0B | $1.8B | ||
| Q2 24 | $2.9B | $1.8B | ||
| Q1 24 | $2.6B | $1.8B |
负债/权益比PODDSCSC
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.64× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.72× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.3M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | $48.2M | $28.9M |
| 自由现金流率自由现金流/营收 | 6.2% | 3.8% |
| 资本支出强度资本支出/营收 | 17.2% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.80× | 1.87× |
| 过去12个月自由现金流最近4个季度 | $377.7M | — |
8季度趋势，按日历期对齐
经营现金流PODDSCSC
| Q4 25 | $183.3M | $30.8M | ||
| Q3 25 | $125.7M | $23.2M | ||
| Q2 25 | $196.5M | — | ||
| Q1 25 | $63.8M | $66.1M | ||
| Q4 24 | $147.7M | $-6.2M | ||
| Q3 24 | $98.5M | $44.8M | ||
| Q2 24 | $96.5M | — | ||
| Q1 24 | $87.6M | $160.2M |
自由现金流PODDSCSC
| Q4 25 | $48.2M | $28.9M | ||
| Q3 25 | $100.1M | $20.8M | ||
| Q2 25 | $177.9M | — | ||
| Q1 25 | $51.5M | $64.6M | ||
| Q4 24 | $94.1M | $-8.2M | ||
| Q3 24 | $71.8M | $42.5M | ||
| Q2 24 | $74.0M | — | ||
| Q1 24 | $65.5M | $157.7M |
自由现金流率PODDSCSC
| Q4 25 | 6.2% | 3.8% | ||
| Q3 25 | 14.2% | 2.8% | ||
| Q2 25 | 27.4% | — | ||
| Q1 25 | 9.1% | 9.2% | ||
| Q4 24 | 15.7% | -1.1% | ||
| Q3 24 | 13.2% | 5.5% | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | 14.8% | 21.0% |
资本支出强度PODDSCSC
| Q4 25 | 17.2% | 0.3% | ||
| Q3 25 | 3.6% | 0.3% | ||
| Q2 25 | 2.9% | 0.3% | ||
| Q1 25 | 2.2% | 0.2% | ||
| Q4 24 | 9.0% | 0.3% | ||
| Q3 24 | 4.9% | 0.3% | ||
| Q2 24 | 4.6% | 0.2% | ||
| Q1 24 | 5.0% | 0.3% |
现金转化率PODDSCSC
| Q4 25 | 1.80× | 1.87× | ||
| Q3 25 | 1.43× | 1.17× | ||
| Q2 25 | 8.73× | — | ||
| Q1 25 | 1.80× | 3.79× | ||
| Q4 24 | 1.47× | -0.36× | ||
| Q3 24 | 1.27× | 2.64× | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 1.70× | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
